Overview of biomarkers and surrogate endpoints in drug development

Disease Markers

Volumn 18, Issue 2, 2002, Pages 41-46

  Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acrp30; Adiponectin; Biomarkers; Clinical endpoint; Pharmacodynamic marker; PPAR ; Surrogate endpoint; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADIPOCYTE; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; DRUG RESEARCH; GENE EXPRESSION; GENETIC COMPLEMENTATION; HUMAN; IN VIVO STUDY; LABORATORY TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESEARCH; REVIEW; TECHNOLOGY; VALIDATION PROCESS;

EID: 0036399255     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/929274     Document Type: Review

References (21)

1. A.H. Berg, T.C. Combatsiaris, X. Du, M. Brownlee and P.E. Scherer, 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med 7 (2001), 947-953.
2. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Therapeutics 69 (2001), 89-95.
3. J.W. Blue and W.A. Colburn, Efficacy measures: surrogates or clinical outcomes, J Clin Pharmacol 36 (1996), 767-770.
4. T.P. Combs, J.A. Wagner, J. Berger, T.W. Doebber, W.-J. Wang, B.B. Zhang, M. Tanen, A.H. Berg, S. O'Rahilly, D.B. Savage, K. Chatterjee, S. Weiss, P.J. Larson, K.M. Gottesdiener, B.J. Gertz, M.J. Charron, P.E. Scherer and D.E. Moller, Induction of Acrp30 levels by PPARgamma agonists: a potential mechanism of insulin sensitization, Endocrinology 143 (2002), 998-1007.
5. S.G. Darvey and J. Pekkanen, Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304 (1992), 431-434.
6. K. Das, Y. Lin, E.Y.Z. Widen and P.E. Scherer, Chromosomal localization, expression pattern and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30, Biochem. Biophys. Res. Comm. 280 (2001), 1120-1129.
7. D.S. Echt, P.R. Liebon, B. Mitchell, R.W. Peters and D. Obias-Manno, Mortality and morbidity of patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial, N Engl J Med 324 (1991), 781-788.
8. J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R. Erickson, F.T. Yen, B.E. Bihain and H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci USA 98 (2001), 2005-2010.
9. E. Hu, P. Liang and B.M. Spiegelman, AdipoQ is a novel adipose-specific gene dysregulated in obesity, J Biol Chem 271 (1996), 10697-10703.
10. L.J. Lesko and A.J. Atkinson, Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies, Annu Rev Pharmacol Toxicol 41 (2001), 347-366.
11. I.C. Marschner, A.C. Collier, R.W. Coombs, R.T. D'Aquila and V. Dgruttola, Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy, J Infect Disease 177 (1998), 40-47.
12. M.J.T.M. Mol, D.W. Erkelens, J.A. Gevers Leuven, J.A. Schouten and A.F.H. Stalenhoef, Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia, Lancet 2 (1986), 936-939.
13. M.F. Muldoon, S.B. Manuck and K.A. Matthews, Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials, BMJ 301 (1990), 309-314.
14. M.F. Oliver, Doubts about preventing coronary heart disease: multiple interventions in middle aged men may do more harm than good, BMJ 304 (1992), 393-394.
15. P. Rolan, The contribution of clinical pharmacology surrogates and models to drug development: a critical appraisal, Br J Clin Pharmacol 44 (1997), 219-225.
16. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994), 1383-1389.
17. P.E. Scherer, S. Williams, M. Fogliano, G. Baldini and H.F. Lodish, A novel serum protein similar to C1q, produced exclusively in adipocytes, J Biol Chem 270 (1995), 26746-26749.
18. L. Shapiro and P.E. Scherer, The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor, Curr Biol 8 (1998), 335-338.
19. Y. Wang, A. Xu, C. Knight, L.Y. Xu and G.J.S. Cooper, Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity, J Biol Chem. (2002), (in press).
20. T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami and N. Tsuboyama-Kasaoka et al., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nature Med. 7 (2001), 941-946.
21. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, Y. Matsuzawa, J.P. Wang, C.L. Chen, T.Y. Tai and L.M. Chuang, Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care 25 (2002), 376-380.